Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis

The Journal of Pediatrics

Volumn 116, Issue 6, 1990, Pages 960-964

  Caplan, Michael S ^a,b   Sun, Xiao Ming ^a,b   Hsueh, Wei ^a,b   Hageman, Joseph R ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; NECROTIZING ENTEROCOLITIS; NEWBORN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ENTEROCOLITIS, PSEUDOMEMBRANOUS; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMAN; INFANT, NEWBORN; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PLATELET COUNT; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0025296725     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(05)80661-4     Document Type: Article

References (29)

1. Necrotizing enterocolitis
2. Paf-acether, an ether phospholipid with biological activity
3. Platelet activating factor a biologically active phosphoglyceride
4. Experimental model of ischemic bowel necrosis the role of platelet-activating factor and endotoxin
5. Platelet activating factor is an endogenous mediator for bowel necrosis in endotoxemia
6. Cachectin/tumour necrosis factor
7. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin
8. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet activating factor
9. Necrotizing enterocolitis: treatment based on staging criteria
10. Neonatal necrotizing enterocolitis therapeutic decisions based upon clinical staging
11. A simple method for the isolation and purification of total lipides from animal tissues
12. Selection of macrophage resistant progressor tumor variants by the normal host
13. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease
14. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists
15. Acute hypoxia induces PAF release in the rat [Abstract]
16. Shock and tissue injury induced by recombinant human cachectin
17. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
18. 2 production by human synovial cells and dermal fibroblasts
19. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet activating factor
20. PAF-like activity in the plasma from patients with septicemia and other disease
21. Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats
22. Human serum acid-labile factor is a acylhydrolase that inactivates platelet activating factor
23. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children
24. Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura
25. Tumor necrosis factor and disease severity in children with falciparum malaria
26. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome
27. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo
28. Detection of circulating tumor necrosis factor after endotoxin administration
29. Tumor necrosis factor/cachectin and interleukin-1 secretion by cord blood monocytes from premature and term neonates